TScan Therapeutics (NASDAQ: TCRX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-18 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.670 | ||||||
REV | 3.021M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.
Other companies in TScan Therapeutics’s space includes: Alzamend Neuro (NASDAQ:ALZN), Orchard Therapeutics (NASDAQ:ORTX), Galectin Therapeutics (NASDAQ:GALT), 89bio (NASDAQ:ETNB) and Bolt Biotherapeutics (NASDAQ:BOLT).
The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Tuesday, May 10, 2022. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 376.95% upside). 5 analyst firms have reported ratings in the last year.
The stock price for TScan Therapeutics (NASDAQ: TCRX) is $3.145 last updated June 30, 2022, 8:00 PM UTC.
A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.
TScan Therapeutics’s Q2 earnings are confirmed for Thursday, August 18, 2022.
There is no upcoming split for TScan Therapeutics.
TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.